Tacrolimus Market Report 2026

The tacrolimus market size has grown strongly in recent years. It will grow from $6.97 billion in 2025 to $7.39 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to growth in organ transplantation procedures, proven clinical efficacy of tacrolimus, increasing prevalence of autoimmune and inflammatory conditions, improved transplant success rates, expanding healthcare infrastructure for transplant care.

The tacrolimus market size is expected to see strong growth in the next few years. It will grow to $9.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising number of kidney and liver transplants, growing demand for cost-effective generic drugs, increasing off-label use in dermatology, advancements in immunosuppressive drug monitoring, expanding transplant programs in emerging economies. Major trends in the forecast period include rising demand for post-transplant immunosuppressive therapies, growing use of tacrolimus in dermatological applications, increasing preference for generic immunosuppressant drugs, expansion of long-term organ transplant survival rates, higher adoption of topical tacrolimus formulations.

The rising number of organ transplant procedures is anticipated to drive the growth of the tacrolimus market in the coming years. Organ transplantation involves the surgical replacement of a failing organ by transferring an organ or tissue from a donor to a recipient. The demand for organ transplants is increasing due to advancements in medical technology, improvements in surgical techniques, greater awareness of organ donation, and enhanced post-transplant care. Tacrolimus supports organ transplantation by inhibiting T-cell activation and reducing cytokine production, thereby preventing the immune system from rejecting the transplanted organ. For example, in January 2025, the Organ Procurement and Transplantation Network, a US-based non-profit organization, reported a slight increase in kidney transplants, reaching 27,759 in 2024, up 1.6 percent from 2023. In comparison, the number of heart transplants remained nearly unchanged, with 4,572 procedures in 2024 versus 4,545 in 2023. Consequently, the growth in organ transplant procedures is fueling the tacrolimus market.

The growing elderly population is anticipated to boost the tacrolimus market's expansion. The elderly population includes individuals generally aged 65 and above, who often face distinct healthcare, social, and physiological challenges linked to aging. This rise stems mainly from longer life expectancies, enabled by advances in healthcare, superior disease control, and improved living standards. Tacrolimus aids this group by regulating immune responses to avert organ rejection and treat autoimmune disorders, tackling the heightened risk of immune issues in older people. For instance, in July 2024, the UK Parliament's House of Commons Library - a UK government body - reported that 12.7 million people aged 65 or older lived in the UK in 2022, making up 19% of the total population. This figure is expected to climb to 22.1 million by 2072, comprising 27% of the population. Thus, the expanding elderly population is fueling tacrolimus market growth.

Major companies in the tacrolimus market are creating advanced drugs, like tacrolimus ointments, to address the rising need for novel therapies against dermatological issues and improve patient outcomes. Tacrolimus ointment serves as a topical remedy with tacrolimus, an immunosuppressive drug mainly applied to inflammatory skin disorders. For example, in August 2023, Glenmark, an Indian pharmaceutical firm, secured US FDA approval for Tacrolimus Ointment 0.03%, the generic version of Protopic Ointment 0.03%. Glenmark Pharmaceuticals will handle distribution of Tacrolimus Ointment, 0.03%, across the United States. This drug treats moderate-to-severe atopic dermatitis, a condition leading to skin inflammation, redness, and itching.

Major companies operating in the tacrolimus market are Astellas Pharma Inc, Novartis AG, Abbott Laboratories, Viatris Inc., Teva Pharmaceutical Industries Limited, Sandoz Inc, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Hikma Pharmaceuticals, Biocon Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Wockhardt Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Huadong Medicine Co Ltd, Glenmark Pharmaceuticals Ltd., Panacea Biotec.

North America was the largest region in the tacrolimus market in 2025. The regions covered in the tacrolimus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tacrolimus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the tacrolimus market by increasing the cost of imported active pharmaceutical ingredients, excipients, and sterile manufacturing inputs used in both oral and injectable formulations. These impacts are most evident in regions that rely heavily on cross border api sourcing, particularly for immunosuppressive drug production. Rising input costs have placed pressure on pricing structures and influenced hospital and pharmacy procurement decisions. At the same time, tariffs are encouraging investments in local api manufacturing, domestic formulation facilities, and supply chain localization strategies. This shift is gradually strengthening regional self sufficiency and long term supply stability within the market.

The tacrolimus market research report is one of a series of new reports that provides tacrolimus market statistics, including tacrolimus industry global market size, regional shares, competitors with a tacrolimus market share, detailed tacrolimus market segments, market trends and opportunities, and any further data you may need to thrive in the tacrolimus industry. This tacrolimus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tacrolimus is a medication that suppresses the immune system and is used to prevent organ rejection after transplantation. It works by reducing immune system activity to prevent the transplanted organ from being attacked. Tacrolimus is prescribed to prevent transplant rejection in cases involving the kidney, heart, liver, or lung.

The main product types of tacrolimus include tacrolimus capsules and tablets, tacrolimus ointment, tacrolimus injection, and tacrolimus granules. Tacrolimus capsules and tablets are forms of medication that contain tacrolimus, a compound used to prevent organ rejection following transplantation. It is used for various applications, including immunosuppression, dermatitis, and other conditions, serving different end users such as organ transplant centers, hospitals, clinics, and more.

The tacrolimus market consists of sales of oral suspension, extended-release capsules, and extended-release tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.